Methods and reagents for treating glucose metabolic disorders

• US 7,396,809 B1
• Filed: 02/10/2000
• Issued: 07/08/2008
• Est. Priority Date: 02/10/1999
• Status: Expired due to Fees

• Current Assignee: Curis, Inc.
• Original Assignee: Curis, Inc.
• Inventors: Pang, Kevin, Lu, Kuanghui
• Primary Examiner(s): Allen; Marianne P.
• Assistant Examiner(s): Deberry; Regina M
• Application Number:
  US09/499,526
• Time in Patent Office: 3,071 Days
• Field of Search: 530/31, 530/326, 530/327, 530/306
• US Class Current: 514/6.9
• CPC Class Codes: A01K 2217/054 inducing loss of function
• CPC Class Codes: A01K 67/0275 Genetically modified vertebrates, e.g. transgenic
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 38/26 Glucagons
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/48 of the pancreatic hormones
• CPC Class Codes: A61P 5/50 for increasing or potentiating the activity of insulin
• CPC Class Codes: G01N 33/507 Pancreatic cells

Abstract

The invention relates to methods for potentiating, enhancing or restoring glucose responsivity in pancreatic islets or cells. The methods can be used as therapies for diseases caused by, or coincident with, aberrant glucose metabolism, such as Type II Diabetes Mellitus.

Claims

1. A method for inducing or enhancing the glucose-responsiveness of a pancreatic cell, which pancreatic cell has impaired cell function and which cell function is glucose-responsiveness, comprising administering to said pancreatic cell an amount of a PYY agonist or a biologically active fragment thereof, wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence wherein the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2×

SSC at 65°

C., to SEQ ID NO;

1, wherein the amount of said PYY agonist or biologically active fragment thereof is sufficient to induce or enhance the glucose-responsiveness of said pancreatic cell, and wherein said PYY agonist or biologically active fragment thereof binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

2. The method of claim 1, whereby administration of the PYY agonist causes the cell to produce insulin when contacted with glucose.

3. The method of claim 1, wherein the cell is a fetal islet cell.

4. The method of claim 1, wherein the cell is a fetal pancreatic cell.

5. The method of claim 4, wherein the cell is a pancreatic β

cell.

6. The method of claim 1, wherein the cell is a postpartum islet cell.

7. The method of claim 1, wherein the cell is a postpartum cell.

8. The method of claim 7, wherein the cell is a pancreatic β

cell.

9. The method of claim 1, wherein the cell is a pancreatic β

cell.

25. The method of any one of claims 1 and 2,3,4,6,7,9, wherein said PYY agonist is administered together with at least one of a dipeptidylpeptidase inhibitor, insulin, or GLP-1.

26. The method of claim 25, wherein said dipeptidylpeptidase inhibitor is DPIV.

27. The method of any one of claims 1 and 2,3,4,6,7,9, wherein said PYY agonist is conjointly administered either simultaneously, sequentially, or separately with at least one of a dipeptidylpeptidase inhibitor, insulin, or GLP-1.

30. The method of any one of claims 1 and 2,3,4,6,7,9, wherein said PYY agonist enhances or recovers glucose responsiveness.

61. The method according to any one of claims 1, 10, 15, 28, 31, 33, 34, 35, 40, 41, 42, 43, 44, or 49 wherein said PYY agonist or biologically active fragment also inhibits intestinal motility.

62. The method according to any one of claims 1, 10, 15, 28, 31, 33, 34, 35, 40, 41, 42, 43, 44, or 49 wherein said PYY agonist or biologically active fragment also inhibits mesenteric blood flow.

63. The method according to any one of claims 1, 10, 15, 28, 31, 33, 34, 35, 40, 41, 42, 43, 44, or 49 wherein said PYY agonist or biologically active fragment also mediates gastric, pancreatic, or intestinal exocrine secretion.

64. The method according to any one of claims 1, 10, 15, 28, 31, 33, 34, 35, 40, 41, 42, 43, 44, or 49 wherein said PYY agonist or biologically active fragment also stimulates net absorption of nutrients.

10. A method for inducing or enhancing glucose metabolism in an animal having a disease associated with abnormal glucose metabolism, comprising administering to said animal a composition including an amount of a PYY agonist or a biologically active fragment thereof, wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence wherein the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2×

SSC at 65°

C., to SEQ ID NO;

1, wherein the amount of said PYY agonist or biologically active fragment thereof is therapeutically effective to induce or enhance glucose metabolism in said animal, and wherein said PYY agonist or biologically active fragment thereof binds a PYY receptor and promotes glucose responsiveness.

11. The method of claim 10, wherein said animal is selected from the group consisting of a human and a rat.

12. The method of claim 10, wherein said composition further comprises at least one of a dipeptidylpeptidase inhibitor, insulin or GLP-1.

13. The method of claim 10, wherein said composition is conjointly administered either simultaneously, sequentially or separately with at least one of a dipeptidylpeptidase inhibitor, insulin or GLP-1.

14. The method of claim 10, wherein said PYY agonist enhances or recovers glucose responsiveness.

60. The method according to any one of claims 10, 15, 34, 35, or 49 wherein said PYY agonist or biologically active fragment also promotes glucose-responsiveness of pancreatic cells.

15. A method for treating a disease associated with altered glucose metabolism, comprising administering to an animal having a disease associated with altered glucose metabolism a composition comprising an amount of a PYY agonist or a biologically active fragment thereof, wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence wherein the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2×

SSC at 65°

C., to SEQ ID NO;

1, wherein the amount of said PYY agonist or biologically active fragment thereof is sufficient to treat the disease, and wherein said PYY agonist or biologically active fragment binds a PYY receptor and promotes glucose responsiveness.

16. The method of claim 15, wherein said disease is a condition selected from insulin resistance, glucose intolerance or glucose non-responsiveness.

17. The method of claim 15, wherein said disease is Type II diabetes mellitus (NIDD).

18. The method of claim 15, wherein said composition further comprises at least one of a dipeptidylpeptidase inhibitor, insulin or GLP-1.

19. The method of claim 15, wherein said composition is conjointly administered either simultaneously, sequentially or separately with at least one of a dipeptidylpeptidase inhibitor, insulin or GLP-1.

20. The method of claim 15, wherein said PYY agonist enhances or recovers glucose responsiveness.

21. The method of claim 15, wherein said animal is selected from the group consisting of a human and a rat.

22. The method of claim 15, wherein said disease is hyperglycemia.

23. The method of claim 15, wherein said disease is obesity.

24. The method of claim 15, wherein said disease associated with altered glucose metabolism comprises hyperlipidemia or hyperlipoproteinemia.

57. The method of any one of claims 15, 35, and 49 to 51, wherein the treatment comprises nasal administration of the composition.

58. The method of any one of claims 15, 35, and 49 to 51, wherein the PYY agonist or fragment is PYY(3-36) of SEQ ID NO:

3.

28. A method for maintaining or restoring a function of a pancreatic β

cell, wherein the function is glucose responsivity or glucose sensing, comprising administering to a pancreatic cell, which pancreatic cell has impaired glucose responsivity or glucose sensing, a composition comprising an amount of a PYY agonist or a biologically active fragment thereof, wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence wherein the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2×

SSC at 65°

C., to SEQ ID NO;

1, wherein the amount of said PYY agonist or biologically active fragment thereof is sufficient to maintain or restore the function of said pancreatic β

cell, and wherein said PYY agonist or biologically active fragment binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

29. The method of claim 28, wherein said PYY agonist enhances or recovers glucose responsiveness.

31. A method for maintaining or restoring normal pancreatic function to a pancreatic cell having impaired pancreatic cell function, wherein the function is glucose responsivity or glucose sensing, comprising administering to a cultured pancreatic cell having altered pancreatic cell function an amount of a PYY agonist or a biologically active fragment thereof, wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence wherein the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2×

SSC at 65°

C., to SEQ ID NO;

1, wherein the amount of said PYY agonist or biologically active fragment thereof is sufficient to maintain or restore normal pancreatic cell function to a pancreatic cell having altered pancreatic cell function, and wherein said PYY agonist or biologically active fragment binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

32. The method of claim 31, wherein the pancreatic cell is a failing β

cell.

33. A method for inducing or enhancing the glucose-responsiveness of a pancreatic cell, which pancreatic cell has impaired glucose-responsiveness, comprising administering to said pancreatic cell an amount of a PYY comprising the amino acid sequence of SEQ ID NO:

2 or a biologically active fragment thereof, wherein the amount of said PYY or biologically active fragment thereof is sufficient to induce or enhance the glucose-responsiveness of said pancreatic cell, wherein the PYY or biologically active fragment thereof binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

34. A method for inducing or enhancing glucose metabolism in an animal having a disease associated with abnormal glucose metabolism, comprising administering to said animal a composition including an amount of a PYY comprising the amino acid sequence of SEQ ID NO:

2 or a biologically active fragment thereof, wherein the amount of PYY or a biologically active fragment thereof is effective to induce or enhance glucose responsiveness in said animal, thereby inducing or enhancing glucose metabolism in said animal, and wherein the PYY or biologically active fragment thereof binds a PYY receptor and promotes glucose responsiveness.

35. A method for treating a disease associated with altered glucose metabolism, comprising administering to an animal having a disease associated with altered glucose metabolism a composition comprising an amount of a PYY comprising the amino acid sequence of SEQ ID NO:

2 or a biologically active fragment thereof, wherein the amount of PYY or a biologically active fragment thereof is sufficient to treat the disease in said animal, and wherein the PYY or biologically active fragment thereof binds a PYY receptor and promotes glucose responsiveness.

36. The method of claim 35, wherein said disease is a condition selected from insulin resistance, glucose intolerance or glucose non-responsiveness.

37. The method of claim 35, wherein said disease is hyperglycemia.

38. The method of claim 35, wherein said disease is obesity.

39. The method of claim 35, wherein said disease associated with altered glucose metabolism comprises hyperlipidemia or hyperlipoproteinemia.

56. The method of any one of claims 35, and 49 to 51, wherein the composition further comprises GLP-1.

59. The method of any one of claims 36 to 39, wherein the biologically active fragment is PYY(3-36) of SEQ ID NO:

3, the composition further comprises GLP-1, and the treatment comprises nasal administration of the composition.

40. A method for maintaining or restoring a function of a pancreatic β

cell, wherein the function is glucose responsivity or glucose sensing, comprising administering to a pancreatic cell, which pancreatic cell has impaired glucose responsivity or glucose sensing, a composition comprising an amount of a PYY comprising the amino acid sequence of SEQ ID NO;

2 or a biologically active fragment thereof, wherein the amount of said PYY or biologically active fragment thereof is sufficient to maintain or restore the function of said pancreatic β

cell, wherein the PYY or biologically active fragment thereof binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

41. A method for maintaining or restoring normal pancreatic cell function, wherein the function is glucose responsivity or glucose sensing, comprising administering to a cultured pancreatic cell, which pancreatic cell has impaired glucose responsivity or glucose sensing, an amount of a PYY comprising the amino acid sequence of SEQ ID NO:

2 or a biologically active fragment thereof, wherein the amount of said PYY or biologically active fragment thereof is sufficient to maintain or restore normal pancreatic cell function, wherein the PYY or biologically active fragment thereof binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

42. A method for maintaining glucose-responsiveness of a pancreatic cell, comprising contacting the pancreatic cell, which pancreatic cell has impaired glucose responsivity or glucose sensing, with a composition comprising an amount of a PYY comprising the amino acid sequence of SEQ ID NO:

2 or a biologically active fragment thereof, wherein the amount of said PYY or biologically active fragment thereof is sufficient to maintain the glucose-responsiveness of the pancreatic cell, wherein the PYY or biologically active fragment thereof binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

47. The method of any one of claims 42-44, wherein the pancreatic cell is a α

, β

, δ

, or φ

-cell.

48. The method of any one of claims 42-44, wherein the pancreatic cell is an insulin-producing cell.

43. A method for maintaining glucose-responsiveness of a pancreatic cell, which pancreatic cell has impaired glucose-responsiveness, comprising contacting said pancreatic cell with a composition comprising an amount of a PYY agonist or a biologically active fragment thereof, wherein the amount of said PYY agonist or biologically active fragment thereof is sufficient to maintain the glucose responsiveness of said pancreatic cell, wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence wherein the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2×

SSC at 65°

C., to SEQ ID NO;

1, and wherein said PYY agonist, or biologically active fragment binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

44. A method for inducing, enhancing, or maintaining glucose-responsiveness of a pancreatic cell, which pancreatic cell has impaired glucose-responsiveness, comprising contacting said pancreatic cell with a composition comprising an amount of a PYY agonist or a biologically active fragment thereof, wherein the amount of said PYY agonist or biologically active fragment thereof is sufficient to induce, enhance, or maintain the glucose-responsiveness of said pancreatic cell, wherein said PYY agonist comprises a polypeptide at least 80% identical with SEQ ID NO:

3, and wherein said PYY agonist, or biologically active fragment binds a PYY receptor and promotes glucose-responsiveness of said pancreatic cell.

45. The method of claim 44, wherein the PYY agonist comprises a polypeptide at least 85% identical to SEQ ID NO:

3.

46. The method of claim 44, wherein the PYY agonist comprises a polypeptide at least 90% identical to SEQ ID NO:

3.

49. A method for treating a disease associated with altered glucose metabolism, comprising administering to an animal having a disease associated with altered glucose metabolism a composition comprising an amount of a PYY agonist or a biologically active fragment thereof effective to treat said disease associated with altered glucose metabolism, wherein said PYY agonist comprises a polypeptide at least 80% identical with SEQ ID NO:

3, and wherein said PYY agonist, or biologically active fragment binds a PYY receptor and promotes glucose responsiveness.

50. The method of claim 49, wherein the PYY agonist comprises a polypeptide at least 85% identical to SEQ ID NO:

3.

51. The method of claim 49, wherein the PYY agonist comprises a polypeptide at least 90% identical to SEQ ID NO:

3.

52. The method of any one of claims 49 to 51, wherein said disease is a condition selected from insulin resistance, glucose intolerance or glucose non-responsiveness.

53. The method of any one of claims 49 to 51, wherein said disease is hyperglycemia.

54. The method of any one of claims 49 to 51, wherein said disease is obesity.

55. The method of any one of claims 49 to 51, wherein said disease associated with altered glucose metabolism comprises hyperlipidemia or hyperlipoproteinemia.

65. A method for maintaining or restoring a function of a pancreatic islet, wherein the function is glucose responsivity or glucose sensing, comprising administering to a pancreatic islet, which pancreatic islet has impaired glucose responsivity or glucose sensing, a composition comprising an amount of a PYY agonist or a biologically active fragment thereof, wherein said PYY agonist comprises the amino acid sequence having a sequence identical to the peptide encoded by the nucleic acid sequence wherein the nucleic acid sequence hybridizes under stringent conditions, including a wash step of 0.2×

SSC at 65°

C., to SEQ ID NO;

1, wherein the amount of said PYY agonist or biologically active fragment thereof is sufficient to maintain or restore the function of said pancreatic islet, and wherein said PYY agonist or biologically active fragment binds a PYY receptor and promotes glucose-responsiveness of said pancreatic islet.